La cadena de opciones muestra datos clave de las opciones de acciones de Hoth Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Hoth Therapeutics..

Hoth Therapeutics (NASDAQ:HOTH) Bolsa, Cadena de Opciones

HOTH THERAPEUTICS INC

Hoth Therapeutics

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Movimientos destacados del premercado: Cal-Maine Foods sube un 3,8%, Sana Biotechnology lidera con un 220,6%.

Las acciones de Cal-Maine Foods suben un 4%; Aquí están 20 acciones que se mueven en el premercado

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Markets

Trading Ideas

APLD

EAST

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SGLY

SIFY

Mercados mixtos en EE.UU. el jueves, con el Nasdaq subiendo un 0,2% y Dow Jones ganando un 0,06%. Sectores de consumo lideran alzas.

Mercados mixtos mientras los subsidios por desempleo de EEUU caen

Barclays analyst Julian Mitchell initiates coverage on Ralliant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAL#NYSE">RAL</a>) with a Overweight rating and announces Price Target of $60.

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On Ralliant with Overweight Rating, Announces Price Target of $60

IMNN

IMUNON Receives Nasdaq Panel Approval To Execute Compliance Plan

Q2 2025 Financial Results Expected to Exceed High End of Guidance Ranges
Jamf expects to exceed the high end of the guidance ranges previously issued with respect to the second quarter of 2025. On May 6, 2025, the company issued the following guidance ranges for the second quarter of 2025:
<ul>
<li>Total revenue of $167.5 to $169.5 million; and</li>
<li>Non-GAAP operating income of $29.5 to $30.5 million.</li>
</ul>
The Company will provide more details regarding the strategic reinvestment plan and its financial impact on subsequent periods during its second quarter 2025 earnings call to be held on August 7, 2025.

Guidance

JAMF

Jamf Sees Q2 2025 Total Revenue Of $167.5M - $169.5M; And Non-GAAP Operating Income Of $29.5M - $30.5M

CMND

Clearmind Expands Phase I/IIa Clinical Trial For CMND-100 With Activation Of Additional Site At Johns Hopkins University School Of Medicine And Enrollment Of First Participant At Clinical Site

Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) narrows FY2025 sales outlook from $83.100 billion-$84.100 billion to $84.000 billion vs $83.840 billion estimate.

Citigroup Narrows FY2025 Sales Guidance from $83.100B-$84.100B to $84.000B vs $83.840B Est

B of A Securities analyst Anna Lizzul maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Buy and lowers the price target from $27 to $25.

KVUE

B of A Securities Maintains Buy on Kenvue, Lowers Price Target to $25

Jamf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>), the standard in managing and securing Apple at work, today announced a strategic reinvestment plan to help drive long-term growth, improve operational efficiency and enhance shareholder value.
Jamf's recent comprehensive systems update, spanning both front- and back-office operations, has provided enhanced insights into Jamf's business and growth opportunities. As a result, Jamf is embarking on a strategic reinvestment plan to support the continued success of the business. This plan includes strategic reallocation of resources to allow for investment in areas with the highest potential to fuel growth and drive additional operational leverage in the business. Two key focus areas are:
1. Go-To-Market Enhancement
Jamf is taking steps to realign its go-to-market organization to allow for investment in areas that have the greatest opportunity for growth and align with our platform strategy via the Jamf for Mac, Jamf for Mobile, Jamf for K-12, and Jamf for SMB solutions.
<ul>
<li>Enhance growth in Enterprise: increasing investment and resources to support Enterprise customers, which deliver higher growth, stronger retention, and greater return on investment.&nbsp;</li>
<li>Simplify approach to SMB: scaling through the channel while also developing a more automated customer solution and experience to deliver greater customer value and improve operational efficiency.</li>
</ul>
2. AI Investments
In addition to the efficiencies experienced over the last year from deploying AI within the sales, product and customer success groups, Jamf is further accelerating investments in AI capabilities that improve the customer experience in the Jamf product platform and drive further productivity enhancements by accelerating delivery of AI- and automation-driven solutions across the entire organization.
In order to facilitate the strategic reinvestment plan, the Company will reduce its workforce by approximately 6.4%. The Company will reduce roles across its go-to-market and other functions to align with the strategic reinvestment plan, as well as reducing spans and layers throughout the organization.
Jamf currently estimates that it will incur charges of approximately $11.0 to $12.5 million in connection with the workforce reduction, consisting of cash expenditures for notice period and severance payments, employee benefits, and related costs. The Company expects that most of the charges will be incurred in the third quarter of 2025 and that the execution of the Plan will be substantially complete by the end of the fourth quarter of 2025. The Company intends to exclude the charges associated with the workforce reduction from certain of its non-GAAP financial measures.&nbsp;

Management

Jamf Launches Strategic Reinvestment Plan With AI Focus, Go-to-Market Realignment, And 6.4% Workforce Reduction; Expects $11M - $12.5M In Restructuring Charges

Contracts

OSS Announces Aggregate $3.9M In New Awards From US-Based Prime Defense Contractor

JMP Securities analyst Jordan Bender maintains Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Market Outperform and raises the price target from $301 to $323.

FLUT

JMP Securities Maintains Market Outperform on Flutter Entertainment, Raises Price Target to $323

CAPT

Captivision Regains Nasdaq Compliance On Market Value And Bid Price Requirements

Biotech

General

ALLR

Allarity Therapeutics Signs Licensing And Laboratory Services Agreement With An EU-Based Biotechnology Company To Supply Transcriptome Analysis Services

COOT

Australian Oilseeds Holdings Partners With SMART MARKETING For Sales, Marketing And Distrbiution Of GEO Brand In Vietnam.

Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension
This patent covers novel cyclic peptides and their use in treating solid tumors

Legal

LSTA

U.S. Patent And Trademark Office Issues Lisata Therapeutics Composition Of Matter Patent For Certepetide Through March 2040 With Opportunity For Patent Term Extension

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, and its clinical development division Sardocor, together with the University of Kansas Medical Center, today announced the successful treatment of the first patient in the MUSIC-DMD Phase 1b clinical trial. The trial is investigating AAV1.SERCA2a, a one-time gene therapy treatment for cardiomyopathy secondary to Duchenne muscular dystrophy (DMD-CM).
The patient was successfully treated via left radial artery access using Medera's proprietary minimally invasive intracoronary infusion methodology. The patient tolerated the procedure well and was discharged following an overnight hospital stay for observation.
The MUSIC-DMD Phase 1b trial is an open-label, controlled study evaluating the safety and efficacy of AAV1.SERCA2a, an adeno-associated virus serotype 1 (AAV1) gene therapy that delivers the SERCA2a gene directly to heart muscle cells, in adult males with DMD-associated cardiomyopathy. The study will enroll up to 12 participants across low-dose, high-dose, and control groups. DMD-associated cardiomyopathy is characterized by calcium overload in heart muscle cells, leading to progressive fibrosis and heart failure. AAV1.SERCA2a aims to restore calcium handling in DMD-CM patients by increasing SERCA2a protein production, potentially reversing the underlying disease process.
 &nbsp;

KVAC

Medera And University Of Kansas Medical Center Announce Treatment Of First Patient In MUSIC-DMD Phase 1b Clinical Trial For Duchenne Muscular Dystrophy

B of A Securities analyst Noah Hungness upgrades National Fuel Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFG#NYSE">NFG</a>) from Underperform to Buy and raises the price target from $85 to $107.

Upgrades

B of A Securities Upgrades National Fuel Gas to Buy, Raises Price Target to $107

<ul>
<li>Mainz Biomed launched eAArly DETECT 2, a US feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over a population of approximately 2,000 patients, all of average risk, to validate the leading results of previous feasibility studies, which included average risk and identified risk patients.</li>
<li>The Company entered into a strategic partnership with labor team w ag, a renowned diagnostic laboratory based in Goldach, Switzerland. This collaboration introduces ColoAlert&#xAE;, a DNA-based colorectal cancer screening test to the Swiss market for the very first time, marking Mainz Biomed's initial footprint in Switzerland.</li>
<li>Mainz Biomed entered into a technology partnership with UK-based EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access the Company's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK.</li>
<li>Mainz Biomed entered into a License and Option Agreement with Liquid Biosciences ("Liquid") to access a portfolio of novel mRNA biomarkers for the non-invasive detection of pancreatic cancer with a blood test.&nbsp;The parties, under the Agreement, plan to develop this blood-based test for potential future FDA applications. The discovery process included multiple independent pancreatic cancer study cohorts. Liquid used their proprietary EMERGE platform to identify a panel of clinically relevant mRNA biomarkers from a blood-based cohort of 285 subjects with 35 pancreatic cancer patients. In the analysis, the biomarkers coupled with the proprietary algorithm developed by Liquid achieved overall sensitivity of 95% and a 98% specificity for the detection of pancreatic cancer. If the statistical results are replicable after the integration into a new product, it has the potential to ultimately position Mainz Biomed's test to be the most robust and accurate screening test for pancreatic cancer on the market.</li>
<li>The Company announced the commencement of the next phase in its PancAlert project, a research initiative focused on developing a non-invasive blood-based screening test for the early detection of pancreatic cancer. The feasibility phase is intended to confirm the discovery analysis performed in early 2025 in partnership with Liquid Biosciences which demonstrated sensitivity of 95% with specificity of 98% for the detection of pancreatic cancer in blood samples.</li>
<li>Mainz Biomed announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB), the development bank of the German federal state of Rheinland-Pfalz. Under the ISB's Innovation and Technology Support Program (Innovations- und Technologieförderungsprogramm), the state will fund up to 50% of the project's total costs. This direct governmental support represents a strong endorsement of the scientific and societal value of the Company's non-invasive, blood-based screening test for the early detection of pancreatic cancer and will accelerate its development.</li>
<li>The Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Listing Rule 5550(b)(1). Mainz Biomed had previously received confirmation that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company is now in full compliance with all Nasdaq continued listing requirements and will continue to be listed and traded on The Nasdaq Capital Market.</li>
<li>Mainz Biomed priced a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant (five-year life) to purchase one ordinary share, and one Series B warrant (one-year life) to purchase one ordinary share for gross proceeds of approximately $4.0 million. Each unit was sold at an effective offering price of $2.00 per unit.</li>
</ul>

MYNZ

Mainz Biomed Reviews H1 2025 Accomplishments; Plans To Complete eAArly DETECT 2 Feasibility Study In H2 2025.

HOVR

HOVRW

New Horizon Aircraft And ZeroAvia Plan To Work Together On Developing Regional Hydrogen-Electric VTOL Air Travel

OFAL

OFA Group Enters Committed Equity Purchase Agreement With Atsion Opportunity Fund LLC – Series 1 For Up To $100M, With Option To Expand To $200M Upon Mutual Agreement

<h3>Gainers</h3>
<ul>
<li>INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) shares moved upwards by 10.2% to $1.3 during Tuesday's pre-market session. The company's market cap stands at $11.6 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) stock rose 9.93% to $1.77. The market value of their outstanding shares is at $1.2 million. </li>
<li>Red Robin Gourmet Burgers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) shares moved upwards by 9.58% to $6.17. The market value of their outstanding shares is at $99.8 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) stock increased by 9.21% to $5.45. The market value of their outstanding shares is at $20.0 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares rose 7.69% to $1.54. The company's market cap stands at $14.2 million. </li>
<li>Aureus Greenway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock increased by 7.43% to $0.65. The company's market cap stands at $8.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kaival Brands Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) stock fell 20.4% to $0.54 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) stock fell 10.66% to $0.55. The market value of their outstanding shares is at $5.2 million. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) shares fell 10.0% to $1.71. The company's market cap stands at $64.1 million. </li>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock fell 7.81% to $0.65. The company's market cap stands at $14.1 million. </li>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) stock declined by 6.4% to $0.25. The company's market cap stands at $30.4 million. </li>
<li>Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) stock decreased by 5.05% to $20.33. The market value of their outstanding shares is at $1.5 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

FTEL

INEO

KAVL

LOBO

RENT

RRGB

RVLV

RYET

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 127.6% to $6.02 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 44.46% to $4.78. The market value of their outstanding shares is at $5.2 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 40.11% to $0.96. The market value of their outstanding shares is at $11.5 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock increased by 20.15% to $3.1. The market value of their outstanding shares is at $96.5 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares rose 19.43% to $14.93. The market value of their outstanding shares is at $24.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares rose 16.85% to $2.53. The company's market cap stands at $3.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Organogenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) stock declined by 24.3% to $3.4 during Tuesday's pre-market session. The company's market cap stands at $569.5 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares declined by 18.05% to $7.9. The company's market cap stands at $30.5 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock decreased by 17.53% to $0.58. The market value of their outstanding shares is at $27.4 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) stock decreased by 17.5% to $3.82. The company's market cap stands at $47.4 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares decreased by 15.6% to $0.4. The market value of their outstanding shares is at $9.7 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares fell 13.82% to $35.0. The market value of their outstanding shares is at $161.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVKD

CYCC

INKT

KAPA

OKYO

ORGO

RANI

SONN

SXTP

TLPH

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Press Releases

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics to Attend 2025 BIO International Convention

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Comments

Hoth Therapeutics

Hoth Therapeutics (HOTH) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL